

## **CURRICULUM VITAE**

***Jonathan H. Schatz, MD***

**1. Date:** 09/11/2015

### **I. PERSONAL DETAILS**

**2. Name:** Jonathan H. Schatz

**4. Office phone:** (305) 243-6520

**5. Address:** 1580 NW 10th Ave, Batchelor Building Room 419, Miami, FL 33136

**6. Current Academic Rank:** Pending Rank at Associate Professor

**6a. Current Track of Appointment:** Tenure-earning track

**7. Primary Department:** Medicine

**8. Secondary or Joint Appointments:** None

**9. Citizenship:** USA

**10. Visa Type:**

### **II. HIGHER EDUCATION**

#### **11. Institutional:**

2004 University of Chicago Pritzker School of Medicine, MD

#### **12. Non-Institutional:**

2004-07 University of Chicago Hospitals, internship/residency in internal medicine (categorical)  
2007-10 Memorial Sloan-Kettering Cancer Center, fellowship in hematology/oncology

#### **13. Licensure and Certification:**

Illinois Medical License (training), 2004-07

New York Medical License, 2007-12

Arizona Medical License (46396), 2012-present

Florida Medical License (ME 124599), June 2015-present.

Board Certified, Internal Medicine, American Board of Internal Medicine, August 2007

Board Certified, Medical Oncology, American Board of Internal Medicine, November 2010

### **III. EXPERIENCE**

#### **14. Academic:**

2010-12 Dept. Medicine, Memorial Sloan-Kettering Cancer Center, Clinical Instructor

2012-15 Dept. Medicine, University of Arizona, Assistant Professor. (Secondary appointment in Dept. Pharmacology/Toxicology)

2015-present Dept. Medicine, University of Miami, Associate Professor (pending committee review)

**15. Hospital Appointments:** None

**16. Non-Academic Appointments:** None

**17. Military:** None

## IV. PUBLICATIONS

### 18. Books and Monographs Published:

### 19. Refereed Journal Articles:

1. Amin AD, Rajan SS, Lang WS, Pongtornpipat P, Groysman MJ, Tapia EO, Tula-Sanchez AA, Peters TL, Cuyugan L, Adkins J, Rimsza LM, Lussier YA, Puvvada SD, **Schatz JH**. Evidence suggesting that discontinuous dosing of ALK kinase inhibitors may prolong control of ALK+ tumors. *Cancer Research*. 2015 Jul 15;75(14):2916-27.
2. Li L, Pongtornpipat P, Tiutan T, Kendrick SL, Park S, Persky DO, Rimsza LM, Puvvada SD, **Schatz JH**. Synergistic Induction of Apoptosis in High-Risk DLBCL by BCL2 Inhibitor ABT-199 Combined with Pharmacologic Loss of MCL1. *Leukemia*. 2015 Aug;29(8):1702-12.
3. Taverna J, Nair A, Yun S, Paulson S, **Schatz JH**, Persky DO, Fuchs D, Puvvada SD. A Rare Presentation of in-situ Mantle Cell Lymphoma and Follicular Lymphoma: A Case Report & Review of the Literature. *Case Rep Hematol*. 2014;2014:145129.
4. **Schatz JH**, Horwitz SM, Teruya-Feldstein J, Lunning MA, Viale A, Huberman K, Socci ND, Lailier N, Heguy A, Dolgalev I, Maragulia J, Pirun M, Palomba ML, Weinstock DM, Wendel HG. Targeted Mutational Profiling of Peripheral T-Cell Lymphoma Not Otherwise Specified Highlights New Mechanisms in a Heterogeneous Pathogenesis. *Leukemia*. 2015 Jan;29(1):237-41.
5. Wolfe AL, Singh K, Zhong Y, Drewe P, Rajasekhar VK, Sanghvi VR, Mavrakis KJ, Roderick JE, Van der Meulen J, **Schatz JH**, Rodrigo CM, Jiang M, Zhao C, Rondou P, de Stanchina E, Teruya-Feldstein J, Kelliher MA, Speleman F, Porco JA, Pelletier J, Rättsch G, Wendel HG. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. *Nature*. 2014; Sep 4;513(7516):65-70.
6. Oricchio E, Ciriello G, Jiang M, Boice MH, **Schatz JH**, Heguy A, Viale A, de Stanchina E, Teruya-Feldstein J, Bouska A, McKeithan T, Sander C, Tam W, Seshan V, Chan J, Chaganti RS, Wendel HG. Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. *Journal of Experimental Medicine*. 2014; 211:1379-1391.
7. Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, **Schatz JH**, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri SA, Harris NL, Ferrero S, Inghirami G, Horwitz SM, Weinstock DM. A Targeted Mutational Landscape of Angioimmunoblastic T-cell Lymphoma. *Blood*. 2014 Feb 27;123(9):1293-6.
8. **Schatz JH**, Oricchio E, Puvvada SD, Wendel HG. Progress Against Follicular Lymphoma. *Current Opinion in Hematology*. *Curr Opin Hematol*. 2013 Jul;20(4):320-6.
9. **Schatz JH**, Wendel HG. Targeted Cancer Therapy: What if the Driver is Just a Messenger? *Cell Cycle*. 2011 Nov 15;10(22):3830-3.
10. Oricchio E, Nanjangud G, Wolfe AL, **Schatz JH**, Mavrakis KJ, Jiang M, Liu X, Bruno J, Heguy A, Olshen AB, Socci ND, Teruya-Feldstein J, Weis-Garcia F, Tam W, Shaknovich R, Melnick AM, Himmanen J, Chaganti RSK, Wendel HG. The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma. *Cell*. 2011;147(3):554-64.
11. **Schatz JH**, Oricchio E, Wolfe AL, Jiang M, Linkov I, Maragulia J, Shi W, Zhang Z, Vinagolu RK, Pagano NC, Porco JA, Teruya-Feldstein J, Rosen N, Zelenetz AD, Pelletier J, Wendel HG. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. *J Exp Med*. 2011 Aug 29;208(9):1799-807.
12. **Schatz JH**. Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin Lymphoma: Results, Biology, and Development Strategies. *Curr Oncol Rep*. 2011 Oct;13(5):398-406.
13. Oricchio E, Wolfe AL, Mavrakis KJ, **Schatz JH**, Wendel HG. Mouse models of cancer as biological filters for complex genomic data. *Dis Model Mech*. 2010 Nov-Dec; 3(11-12):701-4.
14. Jo SH\*, **Schatz JH\***, Acquaviva J\*, Singh H, Ren R. Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis. *Blood*. 2010 Oct 14; 116(15):2759-67. \*Equal contribution.
15. Jhaveri KD, **Schatz JH**, Young JW, Flombaum C. Sirolimus (rapamycin) induced proteinuria in a patient undergoing allogeneic hematopoietic stem cell transplant. *Transplantation*. 2008 Jul 15; 86(1):180-1.

16. Sciammas R, Shaffer AL, **Schatz JH**, Zhao H, Staudt LM, Singh H. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. *Immunity*. 2006 Aug; 25:225-36.

## 20. Other Works, Publications and Abstracts:

1. Soumya Sundara Rajan, Amit Dipak Amin, Matthew Groysman, Praechompoo Pongtornpipat, **Jonathan Schatz**. Over-expression of NPM-ALK drives resistance to TKIs in ALK+ ALCL but is toxic upon drug withdrawal, permitting prolonged tumour control through discontinuous dosing. American Association of Cancer Research Annual Meeting 2015, Abstract #5451 (poster).
2. Matthew Groysman, Amit Dipak Amin, Edgar Tapia, Soumya Rajan, **Jonathan Schatz**. Novel Resistance Mutations to ALK Tyrosine Kinase Inhibition Arising During Cell-Culture Drug Selections in T-Cell Lymphoma. American Society for Biochemistry and Molecular Biology 2015 Annual Meeting, abstract and poster. \*First Place Poster Award, Scientific Theme: "Cancer the War at 44, Warburg at 90"
3. Tara L. Peters, Ana A. Tula-Sanchez, Nicolette Brown, Prae Pongtornpipat, Mengdie Wang, Soham D. Puvvada, **Jonathan H. Schatz**. Activated B-Cell DLBCL with Downstream Activation of Survival Signaling Requires PIM Kinase Activity to Maintain Oncoprotein Translation. American Society of Hematology Annual Meeting 2014, Abstract #4496 (poster).
4. Lingxiao Li, Praechompoo Pongtornpipat, Timothy Tiutan, Samantha L. Kendrick, Soyoun Park, Daniel O Persky, Lisa M. Rimsza, Soham D. Puvvada, and **Jonathan H. Schatz**. Potent Efficacy of BCL2 Inhibition with ABT-199 in High-Risk Aggressive B-Lymphoma Models When Combined with Knockdown of MCL1 American Society of Hematology Annual Meeting 2014, Abstract #506 (oral session).
5. Lingxiao Li, Ph.D., Praechampoo Pongtornpipat, B.S., Soyoun Park, M.D., **Jonathan H. Schatz**, M.D. Targeting MCL1 and BCL2 Simultaneously Shows High Potency Against DLBCL. American Society of Clinical Oncology 2014 Annual Meeting, Abstract #e19509
6. Amit Dipak Amin, Soumya Rajan, Matthew Groysman, Tara Peters, Prae Pongtornpipat, Soham Puvvada and **Jonathan Schatz**. Preclinical models of resistance to ALK-kinase inhibition in anaplastic large-cell lymphoma highlight a potential for intermittent dosing exploiting oncogene overdose. American Society of Hematology Meeting on Lymphoma Biology, 2014 (poster)
7. Tula-Sanchez Ana, Peters Tara, Brown Nicolette, Pongtornpipat Prae, Wang Mengdie, Soham D. Puvvada, **Schatz Jonathan**. Pan-PIM kinase inhibition with LGH447 shows efficacy against ABC-DLBCL but increases PIM levels through reduced protein turnover. ASH Meeting on Lymphoma Biology 2014 (poster)
8. Lingxiao Li, Prae Pongtornpipat, Soham D. Puvvada, and **Jonathan H. Schatz**. Targeting MYC Expression with CDK Inhibitors Shows Potency in Preclinical Models of High-Risk Diffuse Large B-Cell Lymphoma. American Society of Hematology 2013 Annual Meeting, Abstract #1831 (poster)
9. Amit Dipak Amin, Prae Pongtornpipat and **Jonathan Schatz**. Induced Dependence on the ALK Kinase Inhibitor Crizotinib in Formerly Sensitive Anaplastic Large Cell Lymphoma Cells. American Society of Hematology 2013 Annual Meeting, Abstract #3842 (poster)
10. **Jonathan H. Schatz**, Steven M. Horwitz, Matthew A. Lunning, Igor Dolgalev, Kety Huberman, Adriana Heguy, Agnes Viale, Mono Pirun, Nicholas D. Socci, Julie Teruya-Feldstein, and Hans-Guido Wendel. Next-Generation Sequencing Suggests Complex, Heterogeneous Pathogenesis in Peripheral T-Cell Lymphoma Unspecified. American Society of Hematology 2013 Annual Meeting, Abstract #843 (oral session)
11. **Jonathan H. Schatz**, Elisa Oricchio, Man Jiang, Irina Linkov, Jocelyn Maragulia, Weiji Shi, Zhigang Zhang, Julie Teruya-Feldstein, Andrew Zelenetz, and Hans-Guido Wendel. Targeting Cap-Dependent Translation to Bypass Pro-Survival Signaling by AKT and the Pim Family Kinases in Non-Hodgkin Lymphoma. International Congress on Malignant Lymphoma 2011, Lugano, Switzerland (oral session)
12. **Jonathan H. Schatz**, Elisa Oricchio, Man Jiang, Irina Linkov, Jocelyn Maragulia, Weiji Shi, Zhigang Zhang, Julie Teruya-Feldstein, Andrew Zelenetz, and Hans-Guido Wendel. Therapeutic Inhibition of Cap-Dependent Translation Coordinately Blocks Redundant AKT and PIM Kinase Signals in Lymphoma. Geoffrey Beene Cancer Research Center Symposium 2011 (poster)
13. **Jonathan H. Schatz**, Michael Boice, Konstantinos J. Mavrakis, Andrew L. Wolfe, and Hans-Guido Wendel. MicroRNAs Mediate Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive B-ALL

by Down-Regulating Key Tumor Suppressors. 2011 American Society of Hematology Annual Meeting, Abstract #2553 (poster)

14. **Jonathan H. Schatz**, Julie Teruya-Feldstein, Man Jiang, Andrew D Zelenetz, and Hans-Guido Wendel. Targeting Translation Bypasses Pim Kinase Activity, a Common and Adverse Prognostic Marker In Lymphoma. 2010 American Society of Hematology Annual Meeting, Abstract #119 (oral session)
15. **Jonathan H. Schatz**, Julie Teruya-Feldstein, Man Jiang, Andrew D. Zelenetz, and Hans-Guido Wendel. Targeting Translation Bypasses Pim Kinase Activity, a Common and Adverse Prognostic Marker in Lymphoma. Mechanisms and Models of Cancer 2010, Cold Spring Harbor (poster)
16. **Jonathan Schatz** and Hans-Guido Wendel. Oncogenic Pim Kinase Activity Provides Resistance to Mtor Inhibition in Vitro and In Vivo. 2009 American Society of Hematology Annual Meeting, Abstract #3974 (poster)
17. **Jonathan H. Schatz** and Harinder Singh. IRF-4 Functions as a Myeloid Tumor Suppressor. American College of Physicians, Northern Illinois Chapter Scientific Meeting, 2005. \*First Place, Resident Poster Competition, subsequent presentation at the 2006 ACP Annual Meeting, 2006.
18. Jaime Acquaviva\*, **Jonathan Schatz\***, Harinder Singh\*, and Ruibao Ren\*. IRF-4 Functions as a Myeloid Tumor Suppressor. 2006 American Society of Hematology Annual Meeting, Abstract #2206 (poster). \*Equal Contribution
19. **Jonathan Schatz**, Ruibao Ren, and Harinder Singh. Loss of IRF-4 Exacerbates CML-like Phenotype of IRF-8 Knockout Mice": 2004 American Society of Hematology Annual Meeting, Abstract #2952 (poster)
20. **Jonathan Schatz** and Harinder Singh. The Transcription Factors IRF-4 and IRF-8: New Insights on Myeloid Development and the Pathogenesis of Chronic Myeloid Leukemia. 2004 Senior Scientific Forum, University of Chicago Pritzker School of Medicine (oral session).
21. Interleukin 7 and B-Cell Differentiation, a Mutational Analysis of IL-7 Receptor. 2001 Summer Research Forum, University of Chicago Pritzker School of Medicine (oral session).

#### **21. Other Works Accepted for Publication:**

1. Amin AD, Rajan SS, **Schatz JH**. Oncogene Overdose: Achilles' Heel for Kinase-Addicted Cancers? Aging. In Press.
2. Amin AD, Rajan SS, Groysman MJ, Pongtornpipat P, **Schatz JH**. Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells. Biomarkers in Cancer. In Press.

## **V. PROFESSIONAL**

### **22. Funded Research Performed:**

#### **NIH Awards**

Active:

Role: Principal Investigator

Title: A New Treatment Paradigm for ALK-Driven Cancers Exploiting Oncogene Overdose

Funding Agency: NIH/NCI 1R01CA190696-01

Support: \$1,037,500 direct, \$552,297 indirect, \$1,589,797 total (as awarded, final indirect figure pending completion of transfer to U. Miami)

Award Period: 09/19/2014-08/31/2019

Completed:

Role: Principal Investigator of sub-award

Title: Cyclin-Dependent Kinase Inhibition as a Synthetic Lethal Approach in High-Risk Diffuse Large B-Cell Lymphoma with Co-Expression of MYC and BCL2 (Sub-award from U. Arizona Cancer Center Support Grant)

Funding Agency: NIH/NCI P30CA023074-34 (PI: David Alberts)  
Support: \$30,000 (direct only)  
Award Period: 07/01/2013-06/30/2014

Role: Trainee  
Title: Fellowship Training Grant, Memorial Sloan-Kettering Cancer Center  
Funding Agency: NIH/NCI T32-CA009207-32 (PI: Dean Bajorin)  
Award Period: 07/01/2008-06/30/2009

Role: Trainee  
Title: Health Professional Student Short-Term Training Grant, University of Chicago Pritzker School of Medicine  
Funding Agency: NIH/NIGMS T35-GM008140-14 (PI: Eugene Chang)  
Award Period: Summer 2001

### **Foundation Funding**

Completed:

Role: Co-Investigator  
Title: Identification of Novel Therapeutic Targets in Mature T-Cell Lymphomas Through Functional, Genomic, and Immunologic Characterization  
Funding Agency: Cycle for Survival (unnumbered, PI: Steven Horwitz)  
Support: \$300,000 (direct only)  
Award Period: 09/01/2011 – 08/31/2014

Role: Principal Investigator of sub-award  
Title: Defining a Role for Pan-PIM Kinase Inhibition in Non-Hodgkin Lymphoma (sub-award of Institutional Research Grant)  
Funding Agency: American Cancer Society IRG-74-001-35 (PI: Mark Pagel)  
Support: \$15,000 (direct only)  
Award Period: 07/01/2014 – 06/30/2014

Role: Principal Investigator  
Title: Targeting Cap-Dependent Translation to Improve Outcomes in Non-Hodgkin Lymphoma  
Funding Agency: Lymphoma Research Foundation, Career Development Award #192191  
Support: \$225,000 (direct only)  
Award Period: 4/15/2011 – 4/14/2014

Role: Principal Investigator  
Title: The PIM family kinases in oncogenesis and resistance to therapy  
Funding Agency: Sloan-Kettering Institute for Cancer Research, Clinical Scholars Biomedical Fellowship (unnumbered)  
Support: \$93,000 (direct only)  
Award Period: 07/01/2009 – 06/30/2011

Role: Principal Investigator  
Title: Genomics of Peripheral T-Cell Lymphoma  
Funding Agency: Gabrielle's Angel Foundation, support for junior investigator (unnumbered)  
Support: \$25,000 (direct only)  
Award Period: One-time award 02/24/2011

Role: Principal Investigator  
Title: Identification and Characterization of Tumor Suppressor Genes in Follicular Lymphoma  
Funding Agency: American Society of Clinical Oncology, Young Investigator Award (unnumbered)

Support: \$50,000 (direct only)  
Award Period: 07/01/2009 – 06/30/2010

## **Other**

### Active:

Role: Principal Investigator  
Title: Sylvester Professorship, multiple projects  
Funding Agency: University of Miami Sylvester Comprehensive Cancer Center  
Support: \$250,000 (direct only)  
Award Period: 09/01/2015 – 08/31/2020

Role: Principal Investigator  
Title: Institutional laboratory startup funds, multiple projects  
Funding Agency: University of Miami Sylvester Comprehensive Cancer Center  
Award Period: 08/10/2015 – 08/09/2020

### Completed:

Role: Principal Investigator  
Title: Institutional laboratory startup funds, multiple projects  
Funding Agency: University of Arizona Bio5 Institute and Cancer Center  
Award Period: 08/13/2012 - 07/17/2015

Role: Principal Investigator  
Title: Targeting Cap-Dependent Translation to Improve Outcomes in Non-Hodgkin Lymphoma  
Funding Agency: Memorial Sloan-Kettering Cancer Center Translational and Integrative Medicine Research Fund (competitive internal funding, unnumbered)  
Support: \$100,000 (direct only)  
Award Period: 01/01/2011 – 07/06/2012

## **23. Editorial Responsibilities:**

### **Ad. Hoc. Reviewer**

*Cancer Discovery*, 2015-present  
*Haematologica*, 2014-present  
*Blood*, 2013-present

### **Grant Review**

Lymphoma Research Foundation, Scientific Advisory Panel, 2012

## **24. Professional and Honorary Organizations:**

American Association for Cancer Research, member, 2008-present  
American Society of Clinical Oncology (ASCO), member, 2008-present  
American Society of Hematology (ASH), member, 2009-present  
Southwest Oncology Group (SWOG), member, 2012-present (Committees: Lymphoma, Early Therapeutics)

## **25. Honors and Awards:**

1998 Illinois Associated Press Editors Association Editorial Excellence Contest, First Place, Investigative Reporting

- 2003-04 Calvin Fentress Research Fellowship Award, University of Chicago Pritzker School of Medicine
- 2004 Leon O. Jacobson Prize: Best presentation at the Senior Scientific Session of research done in medical school by a non-Ph.D. student in the area of basic science investigation, University of Chicago Pritzker School of Medicine
- 2005 American College of Physicians, Northern Illinois Chapter Scientific Meeting, First Place, Resident Poster Competition
- 2009 Mortimer J. Lacher Fellowship, Memorial Sloan-Kettering Cancer Center
- 2009 American Society of Hematology, Travel Award
- 2011 Leukemia & Lymphoma Society Career Development Program, selected as Special Fellow in Clinical Research (funding declined due to overlap)
- 2011-14 NIH Loan Repayment Program
- 2015- Sylvester Professorship, University of Miami Sylvester Comprehensive Cancer Center, providing \$50,000 per year in unrestricted research funding, five-year initial award

**26. Post-Doctoral Fellowships:** None

**27. Other Professional Activities:**

**Papers Presented (Oral Sessions)**

*Lectures, Memorial Sloan-Kettering Cancer Center (2007 - 2012)*

Emerging Targets: The PIM Family Kinases in Lymphomagenesis and Resistance to Therapy. *Mortimer J. Lacher Fellowship Lecture, May 2009*

Emerging Targets: The PIM Family Kinases in Lymphomagenesis and Resistance to Therapy. *Division of Hematology/Oncology Grand Rounds, October 2009*

Emerging Targets: The PIM Family Kinases in Lymphomagenesis and Resistance to Therapy. *Human Oncology & Pathogenesis Program/Cancer Biology & Genetics Science Club, December 2009*

Targeting Cap-Dependent Translation Bypasses Parallel Survival Signals in Non-Hodgkin Lymphoma. *Human Oncology & Pathogenesis Program/Cancer Biology & Genetics Science Club, June 2011*

*Lectures, University of Arizona (2012 - 2015)*

New Approaches to Overcome Treatment Resistance in Lymphoma. *Cancer Biology Symposium Series, November 2012*

New Drug Strategies for Lymphoma: Looking for Simple Targets in Complex Cancers. *Drug Discovery and Development Seminar Series, April 2013*

Mining Resistance Mechanisms for New Therapeutic Strategies in Lymphoma. *Collaborative Cancer Grand Rounds, February 2014*

Studies of Preclinical Therapeutics and Resistance in Lymphoma Model Systems. *University of Arizona Radiology Research Group, January 2015*

Is Oncogene Overdose a New Achilles Heel for Kinase-Addicted Cancers? *Cancer Biology Research Conference, March 2015*

*National/International Meetings: Oral Presentations and Session Moderation*

2010 Oral session, American Society of Hematology Annual Meeting, Title: "Targeting Translation Bypasses Pim Kinase Activity, a Common and Adverse Prognostic Marker in Lymphoma"

2011 Oral session, International Congress on Malignant Lymphoma, Lugano, Switzerland, "Targeting Cap-Dependent Translation to Bypass AKT and the PIM Family Kinases in Non-Hodgkin Lymphoma"

2013 Oral session, International Congress on Malignant Lymphoma, Lugano, Switzerland, "Next-Generation Sequencing Suggests Therapeutic Targets in Peripheral T-Cell Lymphoma"

2013 Oral session, American Society of Hematology Annual Meeting, "Next-Generation Sequencing Suggests Complex, Heterogeneous Pathogenesis in Peripheral T-Cell Lymphoma Unspecified"

- 2013 Abstract Reviewer and Session Moderator, Biology of Lymphoma, American Society of Hematology Annual Meeting
- 2014 Oral session, American Society of Hematology Annual Meeting, "Potent Efficacy of BCL2 Inhibition with ABT-199 in High-Risk Aggressive B-Lymphoma Models When Combined with Knockdown of MCL1." Senior author, Presenter: Lingxiao Li

*Invited Guest Lectures*

Mining Resistance Mechanisms for New Therapeutic Strategies in Lymphoma. *University of Miami, Hematology/Oncology Grand Rounds, May 2014*  
 Exploring new treatments for lymphoma in the lab. *American Cancer Society, Tucson, AZ Chapter, staff meeting, January 2015*  
 Oncogene Overdose in Cancer Therapy Resistance: Can We Use it to Help Patients? *University of Arizona College of Medicine-Phoenix, Basic Medical Sciences Seminar Series, March 2015*

**Research Trainees**

- 1) Praechampoo Pongtornpipat, B.S., Research Specialist, 2012-2015. Current position: Biology Graduate Student at University of California-San Diego
- 2) Lingxiao Li, Ph.D., Post-Doc, 2013-2015; Laboratory Manager, 2015-present
- 3) Amit D. Amin, Ph.D., Post-Doc, 2013-present
- 4) Matthew J. Groysman, Undergraduate Research Associate, 2013-2015. Current Position: Medical School Applicant
- 5) Ana Tula-Sanchez, Ph.D., Post-Doc, 2013-2014. Current position: Post-Doc for Justina D. McEvoy, UA Department of Molecular and Cellular Biology
- 6) Tara L. Peters, B.S., Graduate Student, UA and UM Cancer Biology Graduate Programs, 2014-present
- 7) Soumya S. Rajan, B.S., Graduate Student, UA and UM Cancer Biology Graduate Programs, 2014-present
- 8) Timothy Tiutan, B.S., UA Medical Student Research Fellow, 2014-2015. Current Position: MS4

**VI. TEACHING**

**28. Teaching Awards Received:** None

**29. Teaching Specialization:**

- 2013 Advanced Topics in Cancer Biology (UA Cancer Biology Graduate Interdisciplinary Program), two-week course block: "Using Cancer Model Systems in Target Discovery and Treatment Resistance"
- 2013-15 UA Undergraduate Biology Research Program (UBRP), full-time summer research student, continuing during the academic year for five credit hours per semester
- 2014 Presentation to UA hematology/oncology fellows: "Follicular Lymphoma in the Clinic and Lab"
- 2014 Lecture, CBIO522: UA Cancer Biology Graduate Seminar: "Cancer Therapeutics"
- 2015 Advanced Topics in Cancer Biology (UA Cancer Biology Graduate Interdisciplinary Program), two-week course block: "Cancer Treatment Resistance"
- 2010-present Teaching medical students, residents, and fellows at attending level

**30. Thesis and Dissertation Advising/Post-doctoral Student Supervision:**

- 1) Rotating first-year graduate students in the laboratory, 1-2 students at a time, up to three three-month blocks per academic year, 2013-present



- 2) Doctoral thesis advisory committee member, Aaron P. Havas, UA Cancer Biology Graduate Interdisciplinary Program, 2013-15. "Role of Cell Cycle in Response to Histone Deacetylase Inhibitor PXD101 in Diffuse Large B-Cell Lymphoma"
- 3) Doctoral thesis advisory committee member, Paul J. Akhenblit, UA Cancer Biology Graduate Interdisciplinary Program, 2014-15. "Measuring Tumor Response to pH Modifying Anti-Cancer Agents with acidoCEST MRI"
- 4) Doctoral thesis advisory committee member, Alejandro M. Chibly, UA Cancer Biology Graduate Interdisciplinary Program, 2014-15. "Regulation of Radiation-Induced Proliferation in Salivary Gland Progenitors by aPKC Polarity"
- 5) Doctoral thesis advisory committee member, Nicolette P. Brown, UA Biochemistry and Molecular & Cellular Biology Graduate Program, 2014-15. "DDX3 and its Role in Medulloblastoma"
- 6) Doctoral thesis advisory committee, Adam Watson, UA Cancer Biology Graduate Interdisciplinary Program, 2015. (Title pending)

## **VII. SERVICE**

### **31. University Committee and Administrative Responsibilities:**

#### **University of Arizona**

2012-15	Member, Cancer Center Scientific Review Committee
2012-15	Practitioner, Lymphoma Clinical Service
2012-15	Faculty, Cancer Biology Graduate Interdisciplinary Program
2013-15	Member, Arizona Health Sciences Center Precision Health Advisory Council
2014	Member, Head-of-Medicine Search Committee (resulted in recruitment of Monica Kraft as Chair, Dept. of Medicine)
2014-15	Member, Cancer Center Space Committee
2014-15	Member, Molecular Oncology/Precision Health Tumor Board
2015	Member, Dept. of Medicine Endocrinology Division Chief Search Committee

#### **Memorial Sloan-Kettering Cancer Center**

2010-12	Member Lymphoma Disease Management Team
2011-12	Member, Molecular Pathology Clinical Testing Advisory Group
2011-12	Member, Peripheral T-Cell Lymphoma Working Group

### **32. Community Activities:**

"Biology of Lymphoma": Leukemia & Lymphoma Society patient information session, New York, NY, 2011